trending Market Intelligence /marketintelligence/en/news-insights/trending/HqLNhXZyLNaxDzW-MTY0kQ2 content esgSubNav
In This List

EMA will review Aeterna Zentaris' drug to assess growth hormone deficiency

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


EMA will review Aeterna Zentaris' drug to assess growth hormone deficiency

The European Medicines Agency accepted for review Aeterna Zentaris Inc.'s Macrilen for the evaluation of adult growth hormone deficiency, or AGHD.

Macrilen, also known as macimorelin, stimulates the secretion of growth hormone from the pituitary gland. Stimulated growth hormone levels are measured in blood samples after oral administration of Macrilen for the assessment of growth hormone deficiency.

AGHD affects about 75,000 adults across the U.S., Canada and Europe. It is characterized by a reduction in bone mineral density, lean body mass, exercise capacity and overall quality of life as well as an increase of cardiovascular risks.

Macimorelin has been granted orphan drug designation by the U.S. Food and Drug Administration for diagnosis of AGHD.